HK1090643A1 - Novel pyridopyrazines and use thereof as kinase modulators - Google Patents

Novel pyridopyrazines and use thereof as kinase modulators

Info

Publication number
HK1090643A1
HK1090643A1 HK06111425.6A HK06111425A HK1090643A1 HK 1090643 A1 HK1090643 A1 HK 1090643A1 HK 06111425 A HK06111425 A HK 06111425A HK 1090643 A1 HK1090643 A1 HK 1090643A1
Authority
HK
Hong Kong
Prior art keywords
kinase modulators
pyridopyrazines
novel
novel pyridopyrazines
modulators
Prior art date
Application number
HK06111425.6A
Other languages
English (en)
Inventor
Eckhard Gunther
Eckhard Claus
Irene Seipelt
Ulf-R Rapp
Ludmilla Wixler
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10323345A external-priority patent/DE10323345A1/de
Priority claimed from DE102004022383A external-priority patent/DE102004022383A1/de
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of HK1090643A1 publication Critical patent/HK1090643A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK06111425.6A 2003-05-23 2006-10-18 Novel pyridopyrazines and use thereof as kinase modulators HK1090643A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10323345A DE10323345A1 (de) 2003-05-23 2003-05-23 Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
DE102004022383A DE102004022383A1 (de) 2004-05-06 2004-05-06 Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
PCT/EP2004/005388 WO2004104003A1 (de) 2003-05-23 2004-05-19 Neue pyridopyrazine und deren verwendung als modulatoren von kinasen

Publications (1)

Publication Number Publication Date
HK1090643A1 true HK1090643A1 (en) 2006-12-29

Family

ID=33477517

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06111425.6A HK1090643A1 (en) 2003-05-23 2006-10-18 Novel pyridopyrazines and use thereof as kinase modulators

Country Status (26)

Country Link
US (1) US7276507B2 (no)
EP (1) EP1636228B1 (no)
JP (2) JP4571944B2 (no)
KR (1) KR101111464B1 (no)
AR (1) AR045686A1 (no)
AT (1) ATE411992T1 (no)
AU (1) AU2004240747B2 (no)
BR (1) BRPI0410633A (no)
CA (1) CA2524525C (no)
CY (1) CY1108715T1 (no)
DE (1) DE502004008322D1 (no)
DK (1) DK1636228T3 (no)
ES (1) ES2316985T3 (no)
HK (1) HK1090643A1 (no)
HR (1) HRP20090036T3 (no)
ME (1) ME00541B (no)
MX (1) MXPA05012645A (no)
NO (1) NO332005B1 (no)
NZ (1) NZ544112A (no)
PL (1) PL1636228T3 (no)
PT (1) PT1636228E (no)
RU (1) RU2330851C9 (no)
SI (1) SI1636228T1 (no)
TW (1) TWI341839B (no)
UA (1) UA78929C2 (no)
WO (1) WO2004104003A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530111A (ja) * 2005-02-14 2008-08-07 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
WO2007054556A1 (de) 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) * 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
EP1785423A1 (de) * 2005-11-11 2007-05-16 Zentaris GmbH Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
EP1990342A1 (en) * 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
JP2013506686A (ja) 2009-09-30 2013-02-28 プレジデント アンド フェロウズ オブ ハーバード カレッジ オートファジー阻害遺伝子産物の変調によりオートファジーを変調する方法
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
CA2943687C (en) 2014-03-26 2024-02-13 Astex Therapeutics Ltd Combinations of an fgfr inhibitor and an igf1r inhibitor
WO2015144804A1 (en) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinations
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN108137546B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途
JP6898919B2 (ja) 2015-09-23 2021-07-07 ヤンセン ファーマシューティカ エヌ．ベー． 新規化合物
US11117894B2 (en) 2017-06-22 2021-09-14 City Of Hope Pyridopyrazine compounds and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
TW274550B (no) * 1992-09-26 1996-04-21 Hoechst Ag
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
UA71555C2 (en) * 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
MXPA04002397A (es) 2001-09-14 2004-12-02 Methylgene Inc Inhibidores de histona deacetilasa.
WO2003086403A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
US20060142178A1 (en) * 2002-04-08 2006-06-29 Barnett Stanley F Method of treating cancer
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
JP4903997B2 (ja) 2002-07-02 2012-03-28 サザン リサーチ インスティチュート ＦｔｓＺの阻害剤およびそれらの用途
CA2500727A1 (en) 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren

Also Published As

Publication number Publication date
EP1636228B1 (de) 2008-10-22
US20040266777A1 (en) 2004-12-30
NO332005B1 (no) 2012-05-21
WO2004104003A1 (de) 2004-12-02
CA2524525C (en) 2012-01-03
TW200505917A (en) 2005-02-16
PT1636228E (pt) 2009-02-02
BRPI0410633A (pt) 2006-06-13
JP4571944B2 (ja) 2010-10-27
JP2010209121A (ja) 2010-09-24
RU2005140377A (ru) 2006-05-10
KR101111464B1 (ko) 2012-02-21
RU2330851C2 (ru) 2008-08-10
NO20056032L (no) 2006-02-15
AR045686A1 (es) 2005-11-09
JP5447855B2 (ja) 2014-03-19
EP1636228A1 (de) 2006-03-22
HRP20090036T3 (en) 2009-03-31
ES2316985T3 (es) 2009-04-16
AU2004240747A1 (en) 2004-12-02
UA78929C2 (uk) 2007-04-25
AU2004240747B2 (en) 2008-01-03
DE502004008322D1 (de) 2008-12-04
PL1636228T3 (pl) 2009-04-30
MXPA05012645A (es) 2006-02-08
DK1636228T3 (da) 2009-02-23
CY1108715T1 (el) 2014-04-09
KR20060038376A (ko) 2006-05-03
SI1636228T1 (sl) 2009-04-30
NZ544112A (en) 2010-01-29
ATE411992T1 (de) 2008-11-15
CA2524525A1 (en) 2004-12-02
RU2330851C9 (ru) 2008-10-20
JP2006528223A (ja) 2006-12-14
US7276507B2 (en) 2007-10-02
ME00541B (me) 2011-10-10
TWI341839B (en) 2011-05-11

Similar Documents

Publication Publication Date Title
HK1090643A1 (en) Novel pyridopyrazines and use thereof as kinase modulators
PT1594867E (pt) Fenilacetamidas e sua utilização como moduladores de glucocinase
EP1581309A4 (en) KINASE MODULATORS
GB0300804D0 (en) Compounds and their use
GB0300805D0 (en) Compounds and their use
GB0301143D0 (en) Compounds and their use
GB0317133D0 (en) Compounds and their use
HK1082507A1 (en) Phenylacetamides and their use as glucokinase modulators
GB0321301D0 (en) Compounds and their use
GB0317283D0 (en) Compounds and their use
GB0301146D0 (en) Compounds and their use
GB0301147D0 (en) Compounds and their use
GB0316108D0 (en) Compounds and their use
GB0302930D0 (en) Compounds and their use
GB0302933D0 (en) Compounds and their use
GB0324209D0 (en) Compounds and their use
GB0323470D0 (en) Compounds and their use
GB0323000D0 (en) Compounds and their use
GB0322658D0 (en) Compounds and their use
GB0322011D0 (en) Compounds and their use
GB0321442D0 (en) Compounds and their use
GB0310333D0 (en) Compounds and their use
GB0304819D0 (en) Compounds and their use
GB0320064D0 (en) Compounds and their use
GB0304820D0 (en) Compounds and their use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170519